Bayer, facing tens of thousands of lawsuits over weedkiller Roundup, has set its sights on the Supreme Court. Dale Mullen, partner and co-chair of the business and corporate law section at Whiteford, joins Bloomberg Intelligence litigation analyst Holly Froum on this episode of the Votes and Verdicts podcast to discuss Bayer Monsanto’s appeal to the US Supreme Court of a $1.25 million verdict holding it liable for failing to warn that Roundup causes cancer. They discuss Bayer’s arguments, the company’s chance of success on appeal, risks that remain even if it secures a Supreme Court victory and more. 

Bayer, facing tens of thousands of lawsuits over weedkiller Roundup, has set its sights on the Supreme Court. Dale Mullen, partner and co-chair of the business and corporate law section at Whiteford, joins Bloomberg Intelligence litigation analyst Holly Froum on this episode of the Votes and Verdicts podcast to discuss Bayer Monsanto&rsquo;s appeal to the US Supreme Court of a $1.25 million verdict holding it liable for failing to warn that Roundup causes cancer. They discuss Bayer&rsquo;s arguments, the company&rsquo;s chance of success on appeal, risks that remain even if it secures a Supreme Court victory and more.&nbsp;

Votes and Verdicts is a series that examines the intersection of business, policy and law. It features conversations between Bloomberg Intelligence's team of litigation and policy analysts and thought leaders discussing legal and policy issues affecting markets and business decisions across many sectors.

Votes and Verdicts is a series that examines the intersection of business, policy and law. It features conversations between Bloomberg Intelligence's team of litigation and policy analysts and thought leaders discussing legal and policy issues affecting markets and business decisions across many sectors.

Votes & Verdicts

Bayer Roundup Suit’s SCOTUS Chances, Risks

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/e96989c9-9ca0-4280-b9f3-b46d00ef8328/transcript

What is the Trump administration’s approach to Cuba? How does it differ from President Donald Trump’s first term? And what happens next in the short term and the longer term? Ricardo Herrero, executive director of the Cuba Study Group, joins Bloomberg Intelligence’s Elliott Stein and Nathan Dean on this episode of the Votes and Verdicts podcast to discuss these and other related questions. Herrero also discusses the risks and opportunities for companies operating or seeking to operate in Cuba, and explores implications for banks like Santander and BBVA, for hotels like Melia and Iberostar and for crypto companies like Coinbase, among other sectors.

What is the Trump administration&rsquo;s approach to Cuba? How does it differ from President Donald Trump&rsquo;s first term? And what happens next in the short term and the longer term? Ricardo Herrero, executive director of the Cuba Study Group, joins Bloomberg Intelligence&rsquo;s Elliott Stein and Nathan Dean on this episode of the Votes and Verdicts podcast to discuss these and other related questions. Herrero also discusses the risks and opportunities for companies operating or seeking to operate in Cuba, and explores implications for banks like Santander and BBVA, for hotels like Melia and Iberostar and for crypto companies like Coinbase, among other sectors.

Trump’s Cuba Plan and Business Implications

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/7d7e3688-eef9-40df-a947-b47500b737c9/transcript

What are the impacts of the Trump administration’s rescheduling of state-licensed medical cannabis to Schedule III from Schedule I? Could federal rescheduling extend to recreational marijuana later this year? If so, how should companies, firms and operators prepare for a world where significant tax relief and growth opportunities emerge? Would Congress face pressure to consider a federal tax on the budding sector if broader cannabis reform is in the cards? Foley Hoag Partner Jeffrey Schultz joins Bloomberg Intelligence’s Nathan Dean and Holly Froum on this episode of the Votes and Verdicts podcast to discuss these and other questions facing the industry.

What are the impacts of the Trump administration&rsquo;s rescheduling of state-licensed medical cannabis to Schedule III from Schedule I? Could federal rescheduling extend to recreational marijuana later this year? If so, how should companies, firms and operators prepare for a world where significant tax relief and growth opportunities emerge? Would Congress face pressure to consider a federal tax on the budding sector if broader cannabis reform is in the cards? Foley Hoag Partner Jeffrey Schultz joins Bloomberg Intelligence&rsquo;s Nathan Dean and Holly Froum on this episode of the Votes and Verdicts podcast to discuss these and other questions facing the industry.

Marijuana Rescheduling in Washington

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/e85ac1f7-0d30-45f4-a350-b467012d938d/transcript

UCLA Law Professor William Boyd joins Bloomberg Intelligence litigation analyst Holly Froum on this episode of the Votes and Verdicts podcast to discuss Bayer’s appeal to the US Supreme Court of a $1.25 million verdict holding it liable for failing to warn that weedkiller Roundup causes cancer. They discuss Bayer’s arguments, the arguments’ vulnerabilities and how the court is likely to rule. They also explore the potential immunity Bayer has from future product-liability lawsuits concerning glyphosate products pursuant to a February executive order.

UCLA Law Professor William Boyd joins Bloomberg Intelligence litigation analyst <a href="https://blinks.bloomberg.com/people/profile/20219265">Holly Froum</a> on this episode of the Votes and Verdicts podcast to discuss Bayer&rsquo;s appeal to the US Supreme Court of a $1.25 million verdict holding it liable for failing to warn that weedkiller Roundup causes cancer. They discuss Bayer&rsquo;s arguments, the arguments&rsquo; vulnerabilities and how the court is likely to rule. They also explore the potential immunity Bayer has from future product-liability lawsuits concerning glyphosate products pursuant to a February executive order.

Bayer Appeal of Roundup Suits at Supreme Court

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/36bb5355-337e-41da-9767-b4600134a431/transcript

Bayer Roundup Suit’s SCOTUS Chances, Risks

In 1 playlist(s)

Votes & Verdicts

Social links

Follow podcast

Recent clips